alexa Marvelon Induced Deep Venous Thrombosis: Case Report | OMICS International
Journal of Molecular Immunology
Like us on:
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

Marvelon Induced Deep Venous Thrombosis: Case Report

Zhu X1,3, Han S2, Chen Y3, Shao M1* and Li Y4*

1China Pharmaceutical University, China

2The First Affiliated Hospital of Nanjing Medical University, China

3Jiangsu Institute of Planned Parenthood Research, China

4Nanjing Medical University, China

*Corresponding Author:
Mingli Shao
School of Business
China Pharmaceutical University
E-mail: [email protected]
Ying Li
School of Public Health
Nanjing Medical University
E-mail: [email protected]

Received date: October 26, 2016; Accepted date: November 1, 2016; Published date: November 4, 2016

Citation: Zhu X, Han S, Chen Y, Shao M, Li Y (2016) Marvelon Induced Deep Venous Thrombosis: Case Report. J Mol Immunol 1:103.

Copyright: © 2016 Zhu X, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Journal of Molecular Immunology


We evaluate a case report of Marvelon caused lower extremity deep venous thrombosis in order to provide reference for safety use of oral contraceptives.


Marvelon; Oral contraceptive; Venous thrombosis; Desogestrel; Hypermenorrhea; Trauma; Fraxiparine


Marvelon (desogestrel ethinylestradiol tablets) is one of the thirdgeneration oral contraceptives and has been widely used on the market in China. The main components of Marvelon are desogestrel 0.15 mg/ tablet and ethinylestradiol 0.03 mg/tablet. It has good effect of contraception, but the side effects induced by Marvelon have also been concerned world widely, especially the risk of venous thrombosis [1]. We report and analyse a new case of lower extremity deep venous thrombosis which was caused by Marvelon because of the treatment of uterine hemorrhage in order to provide reference for safety use of oral contraceptives.

Case Report

A 42-year-old woman, presented at the emergency department with pain and swelling in the left lower extremity. 23 days before, she started to take Marvelon pills because of hypermenorrhea. The dosage was suggested for 1 tablet each time, three times a day for the first three days, then reduced to twice a day for the second three days and reduced to once a day for 12 days. When taken pills for 12 days, she felt pain in the left lower extremity and aggravated when walking. 5 days later, the affected lower limb became swelling, so she stopped taking Marvelon and got a thrombolysis treatment by urokinase and salvia in a hospital. 4 days later, she was transferred to a higher-level hospital.

Admission examination found a significant swelling of the left lower extremity and a 4 cm diameter ecchymosis with mild tenderness. By measurement, the left thigh perimeter was 8 cm longer and the left shin perimeter was 5 cm longer than the healthy side respectively. Other physical examinations about artery pulsesuperficial vein varicose joint motion and gastrocnemius muscle tenderness were all negative. Color Doppler ultrasound showed deep venous thrombosisand iliac vein thrombosis of left lower extremity, the venous blood flow of right lower extremity was normal. Look back to her disease history, there were no thrombotic disease, heart disease, diabetes, migraine, depression, smoke and wine hobby. Her family history was negative for hereditary and congenital disease. When using Marvelon, there was no other medication, no long-term bed rest, no history of trauma surgery. The tests of blood routine, blood type, coagulation function and ECG were taken in emergency. The results were all normal except low haemoglobin.

The patient had been told to have an absolute bedrest and raise the affected limb. Then she was treated with fraxiparine, batroxobin etc. for anticoagulation, thrombolysis and antiplatelet immediately. She was also administrated antibiotics to prevent infection.

After 5 days of therapy, the left lower limb swelling improved as the perimeter of thigh was 6 cm longer and the perimeter of shin was 3 cm longer than that of the healthy side. The therapy was continued until the patient was discharged from hospital 12 days later. Then she was taken a hysteroscopy for seeking the abnormal bleeding reason and confirmed endometrial polyps finally.


Oral contraceptives increase the risk of venous thrombosis, with the extent depending on the dose of ethinylestradiol and the type of progestin [2]. It is reported that the combined hormonal contraceptives with desogestrel confer a six-fold increased risk of venous thrombosis as compared with nonusers [3]. A dose related effect of ethinylestradiol was observed for desogestrel with higher doses being associated with higher thrombosis risk [4]. Although the estrogen (ethinylestradiol) contented in each tablet is very low, but it still leads to resistance to activated protein C(APC)which may serve as marker for the risk of venous thrombosis [5].


Although the incidence of venous thrombosis serious adverse reactions caused by Marvelon is rare, but all women who use oral combined hormonal contraceptives are at risk of venous thrombosis and should be informed of this potentially serious adverse effect. This report will offer a reference to the safety use of oral contraceptives.


The Research is funded by National Natural Science Foundation of Project (30972542).


Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Relevant Topics

Recommended Conferences

Article Usage

  • Total views: 8324
  • [From(publication date):
    December-2016 - Feb 22, 2018]
  • Breakdown by view type
  • HTML page views : 8240
  • PDF downloads : 84

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals


[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version